FANJ
NBIX icon

Financial Architects (New Jersey)’s Neurocrine Biosciences NBIX Stock Holding History

Financial Architects (New Jersey)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,200
Closed -$102K – 1113
2019
Q2 		$102K Buy
1,200
+500
+71% +$41.1K 0.02% 371
2019
Q1 		$62K Buy
+700
New +$58.5K 0.01% 555

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s NBIX Position: Q3 2019 in Review

Financial Architects (New Jersey) sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 17 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in NBIX in Q2 2018 and held it in 5 quarters. The position peaked at $170K in Q3 2018. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Financial Architects (New Jersey) reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 17 Neurocrine Biosciences shares in Q3 2019, an estimated $1K.
  • Financial Architects (New Jersey) first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 5 quarters.
  • Financial Architects (New Jersey)'s Neurocrine Biosciences position peaked at $170K in Q3 2018.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2019, filed 6 Nov 2019.